ANGLE plc (GB:AGL) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ANGLE plc, a leading liquid biopsy company, has entered into an agreement with NuProbe to secure an exclusive global license for a next-generation sequencing (NGS) assay, enhancing the analysis of circulating tumor cells (CTCs) and ctDNA from a single blood sample. This collaboration aims to advance ANGLE’s pharma services and provide highly sensitive cancer mutation detection, which has significant implications for personalized treatment plans in oncology. The company has already demonstrated the NGS panel’s efficacy in identifying mutations across various cancer types, underscoring the potential for improved clinical outcomes.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.